R.A. Schmid

Type de document

Articles (13)

Co-auteur

Date

Source

Mot-clé

Lungs (12) Cancer (12) Patients (11) Lungs--Cancer (11) Patients (11) Treatment (10) Human beings (10) thérapie (9) survie (9) Therapeutics (9) Survival (9) Tumors (7) Older people (7) analyse (6) Expression (6) Analysis (6) protéine (5) cancer (5) Cancer (5) Inhibitors (5) Prognosis (5) Manufacturers' agents (5) Commission merchants (5) Tumors (5) Prognosis (5) tissu (corporel) (4) Chemotherapy (4) Cases (4) Chemotherapy (4) Cells (4)

Documents écrit par R.A. Schmid (13) | parle de R.A. Schmid (0)

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.
H. Yang et al. (10 févr. 2023)
The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer.
P. Zens et al.
Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastases-a Single-Center Study in 190 Patients.
A. Kündig et al.
Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology.
T. Kunzke et al. (1 déc. 2021)
Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.
E. Vassella et al.
Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy.
T. Losmanova et al. (13 oct. 2021)
A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer.
X. Wang et al.
A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
P. Zens et al.
CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer.
Z. Yang et al. (1 juin 2021)
Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).
Y. Gao et al. (19 avr. 2021)
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study.
C. Lu et al.
Chaperone-Mediated Autophagy Markers LAMP2A and HSC70 Are Independent Adverse Prognostic Markers in Primary Resected Squamous Cell Carcinomas of the Lung.
T. Losmanová et al. (2020)
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
D.C. Betticher et al. (2006)